Ratings by Rodman & Renshaw (Michael King Jr.)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/31/2026 | QNTM | New Coverage | Buy (N/A) |
3.08 (3.04) |
-1.3% | Details | ||
| 7/30/2026 | Actuate Therapeutics | ACTU | New Coverage | Buy (N/A) |
1.08 (1.54) |
42.59% | Details | |
| 7/7/2026 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
2.28 (2.42) |
6.14% | Details | |
| 6/30/2026 | vTv Therapeutics | VTVT | New Coverage | Buy (N/A) |
36.27 (31.95) |
-11.91% | Details | |
| 6/15/2026 | Elicio Therapeutics | ELTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | Kyntra Bio | KYNB | New Coverage | Buy (N/A) |
6.63 (7.95) |
19.91% | Details | |
| 5/28/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
5.28 (4.07) |
-22.92% | Details | |
| 5/11/2026 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
3.51 (3.83) |
9.12% | Details | |
| 4/15/2026 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
3.15 (2.03) |
-35.56% | Details | |
| 3/17/2026 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
1.54 (0.14) |
-90.91% | Details | |
| 3/9/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Buy (N/A) |
8.77 (1.85) |
-78.91% | Details | |
| 3/9/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.63 (2.56) |
-77.99% | Details | |
| 1/13/2026 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
1.35 (1.10) |
-18.52% | Details | |
| 1/13/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
28.38 (16.23) |
-42.81% | Details | |
| 1/13/2026 | Biomea Fusion Inc. | BMEA | New Coverage | Buy (N/A) |
1.46 (1.80) |
23.29% | Details | |
| 1/13/2026 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
0.31 (1.74) |
461.29% | Details | |
| 1/13/2026 | Jasper Therapeutics | JSPR | New Coverage | Buy (N/A) |
1.48 (0.70) |
-52.7% | Details |
